I just came across this new study too.
At 24 weeks the high dose (5mg/ml) AR68 maintained just above baseline in both hair density and total hair count, the pictures in my opinion are not massively impressive but technically it did maintain at 24 weeks.
View attachment 175612
View attachment 175613
The most interesting thing for me here actually is that they label AR68 as a
COSMETIC.
"For the development of Androgenetic Alopecia treatment using AR68, AR68 (Cosmerna-68) is listed as a cosmetic ingredient in cosmetic ingredients (ICID) and the Cosmetic Ingredient Dictionary, which are reviewed by the PCPC (Personal Care Products Council) and KCA (Korea Cosmetic Association), respectively. The stability of AR68 nanoparticles in a hair tonic formulation containing cosmetic ingredients was studied by measuring the size of AR68 nanoparticles that remained stable for more than six months."
A cosmetic potentially means that it can
skip the long clinical trial process and we can get our hands on it sooner rather than later.
This is just an assumption but since this decreases the expression of AR mRNA and protein levels, I feel like this treatment won't massively plateau like other drugs that target the AR such as androgen receptor antagonists (Breezula)..
It appears they may be trying to enter the US market as a cosmetic:
"Aside from Bioneer’s progress within the domestic and the European markets for hair loss prevention, siRNAgen is preparing for the U.S. market entrance of CosmeRNA as a hair loss treatment. The existing mechanism, its safety and efficacy shown through human clinical trials were presented during the conference and received many attention from participating companies and investors. The siRNAgen plans to further improve the product profile for the U.S. market in particular, as the product will be developed beyond cosmeceutical use."
Product website:
siRNAgen Therapeutics Corporation is a next-genertion RNAi drug discovery company with SAMiRNA™ (Self-Assembled micellar inhibitory RNA) platform.
www.sirnagen.com
Sources:
siRNAgen Therapeutics is changing the treatment paradigm for patients suffering from chronic immunology and CNS conditions with RNAi therapies
www.sirnagen.com
siRNAgen Therapeutics Corporation is a next-genertion RNAi drug discovery company with SAMiRNA™ (Self-Assembled micellar inhibitory RNA) platform.
www.sirnagen.com
Androgenetic alopecia (Androgenetic Alopecia) is the most common type of hair loss in men and women. Dihydrotestosterone (DHT) and androgen receptor (AR) levels are increased in patients with Androgenetic Alopecia, and DHT-AR signaling correlates strongly with Androgenetic Alopecia pathogenesis. In this study, treatment with self-assembled micelle...
www.nature.com
www.nature.com